Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyronaridine as an Add-on Therapy in Adults With AML or ALL
NCT05291390Phase 2Suspended
- Sponsor
- Armaceutica, Inc.
- Start
- Feb 2028
- Primary completion
- Feb 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pyronaridine in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), sponsored by Armaceutica, Inc.. Planned start Feb 2028; status: suspended.
02
Drugs
pyronaridine
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05291390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05291390.